{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:46:19Z","timestamp":1792565179847,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-026-01962-0","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:21:18Z","timestamp":1792563678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lebrikizumab Provides Stable and Deep Long-Term Response with No\/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct04146363","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04392154","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1605","authenticated-orcid":false,"given":"Linda Stein","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-0152","authenticated-orcid":false,"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jose Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-7340","authenticated-orcid":false,"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-198X","authenticated-orcid":false,"given":"Ken","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-2151","authenticated-orcid":false,"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7354-7402","authenticated-orcid":false,"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5190-4239","authenticated-orcid":false,"given":"Yuxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-8389","authenticated-orcid":false,"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9254-3402","authenticated-orcid":false,"given":"Eric","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8742-8062","authenticated-orcid":false,"given":"Helena","family":"Agell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-3158","authenticated-orcid":false,"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"12","key":"1962_CR1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1962_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/1346-8138.14116","volume":"45","author":"W Wei","year":"2018","unstructured":"Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150\u20137.","journal-title":"J Dermatol"},{"issue":"1","key":"1962_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1962_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1962_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1962_CR6","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"1962_CR7","doi-asserted-by":"publisher","first-page":"18079","DOI":"10.2147\/JIR.S578036","volume":"18","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Chang C, Xiao L, et al. The neuroimmune axis in atopic dermatitis: from pathogenic mechanisms to targeted neuroimmunotherapy. J Inflamm Res. 2025;18:18079\u2013113.","journal-title":"J Inflamm Res"},{"issue":"1","key":"1962_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83\u201390.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"9","key":"1962_CR9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamadermatol.2025.2073","volume":"161","author":"ML Nielsen","year":"2025","unstructured":"Nielsen ML, Nymand LK, Pena AD, Du Jardin KG, Kasujee I, Thomsen SF, et al. Predictors of flares and disease severity in patients with atopic dermatitis using machine learning. JAMA Dermatol. 2025;161(9):950\u20136.","journal-title":"JAMA Dermatol"},{"key":"1962_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7","volume":"37","author":"P Rerknimitr","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14.","journal-title":"Inflamm Regen"},{"issue":"7","key":"1962_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.13911","volume":"28","author":"M Moyle","year":"2019","unstructured":"Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756\u201368.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1962_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1203475420982553","volume":"25","author":"K Ratnarajah","year":"2021","unstructured":"Ratnarajah K, Le M, Muntyanu A, et al. Inhibition of IL-13: a new pathway for atopic dermatitis. J Cutan Med Surg. 2021;25(3):315\u201328.","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"1962_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","volume":"13","author":"AJ Okragly","year":"2023","unstructured":"Okragly AJ, Ryuzoji A, Wulur I, Daniels M, Van Horn RD, Patel CN, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther. 2023;13(7):1535\u201347.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1962_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Thaci D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"5","key":"1962_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14(5):1145\u201360.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1962_CR16","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s13555-025-01481-4","volume":"15","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Sun Z, Mena LR, et al. Lebrikizumab rapidly lowers inflammatory biomarkers with clinical correlations in moderate-to-severe atopic dermatitis. Dermatol Ther. 2025;15(9):2595\u2013614.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1962_CR17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s13555-024-01199-9","volume":"14","author":"PA Lio","year":"2024","unstructured":"Lio PA, Armstrong A, Gutermuth J, et al. Lebrikizumab improves quality of life and patient-reported symptoms of anxiety and depression in patients with moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14(7):1929\u201343.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1962_CR18","doi-asserted-by":"publisher","first-page":"2442720","DOI":"10.1080\/09546634.2024.2442720","volume":"36","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Kircik L, Schlesinger T, et al. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025;36(1):2442720.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1962_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/ced\/llae541","volume":"50","author":"G Yosipovitch","year":"2025","unstructured":"Yosipovitch G, de Bruin-Weller M, Wiseman M, et al. Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol. 2025;50(6):1188\u201392.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1962_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000547142","volume":"241","author":"G Yosipovitch","year":"2025","unstructured":"Yosipovitch G, Lio PA, Rosmarin D, et al. Lebrikizumab improved itch symptoms and reduced itch interference on sleep over 52 weeks in patients with moderate-to-severe atopic dermatitis in two phase 3 trials. Dermatology. 2025;241(4):325\u201335.","journal-title":"Dermatology"},{"issue":"6","key":"1962_CR21","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s13555-026-01771-5","volume":"16","author":"L Stein Gold","year":"2026","unstructured":"Stein Gold L, DeBruin WM, Thaci D, et al. Lebrikizumab ADvocate1 and 2 monotherapy and ADjoin (long-term) trials: use of topicals therapies. Dermatol Ther (Heidelb). 2026;16(6):2757\u201372.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1962_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40257-025-00970-8","volume":"26","author":"A Alexis","year":"2025","unstructured":"Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: results from the phase IIIb, open-label ADmirable study. Am J Clin Dermatol. 2025;26(5):803\u201317.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1962_CR23","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2024.12.026","volume":"92","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, et al. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol. 2025;92(5):1024\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1962_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1962_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13555-024-01226-9","volume":"14","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment. Dermatol Ther. 2024;14(8):2249\u201360.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1962_CR26","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s13555-025-01452-9","volume":"15","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Weidinger S, Simpson EL, et al. Two-year efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis: a long-term extension (ADjoin). Dermatol Ther. 2025;15(8):2217\u201332.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1962_CR27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ced\/llaf490","volume":"51","author":"JI Silverberg","year":"2026","unstructured":"Silverberg JI, Wollenberg A, Stein Gold L, et al. Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis. Clin Exp Dermatol. 2026;51(6):1012\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1962_CR28","doi-asserted-by":"publisher","first-page":"2631233","DOI":"10.1080\/09546634.2026.2631233","volume":"37","author":"E Simpson","year":"2026","unstructured":"Simpson E, Biedermann T, Kircik L, et al. Raising the bar of efficacy in atopic dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years. J Dermatolog Treat. 2026;37(1):2631233.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"1962_CR29","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1007\/s13555-026-01810-1","volume":"16","author":"E Guttman-Yassky","year":"2026","unstructured":"Guttman-Yassky E, Irvine AD, Gooderham M, et al. Three-year efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis: a long-term extension (ADjoin). Dermatol Ther. 2026;16(8):4021\u201339.","journal-title":"Dermatol Ther"},{"key":"1962_CR30","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki 2013 JAMA. 310 20 2191","DOI":"10.1001\/jama.2013.281053"},{"issue":"1","key":"1962_CR31","doi-asserted-by":"publisher","first-page":"2329240","DOI":"10.1080\/09546634.2024.2329240","volume":"35","author":"J Soung","year":"2024","unstructured":"Soung J, Stander S, Gutermuth J, et al. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. J Dermatolog Treat. 2024;35(1):2329240.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1962_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1962_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamadermatol.2024.3054","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Thibau IJC, Mantell B, Dainty KN, Wyke M, Smith Begolka W. Consensus on a patient-centered definition of atopic dermatitis flare. JAMA Dermatol. 2024;160(10):1099\u2013106.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1962_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40257-025-00966-4","volume":"26","author":"JF Merola","year":"2025","unstructured":"Merola JF, Weidinger S, Tan SY, Rahawi K, Gray C. Defining \u201cflares\u201d in atopic dermatitis: a narrative review. Am J Clin Dermatol. 2025;26(6):905\u201321.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1962_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.12747","volume":"170","author":"SM Langan","year":"2014","unstructured":"Langan SM, Schmitt J, Williams HC, Smith S, Thomas KS. How are eczema \u201cflares\u201d defined? A systematic review and recommendation for future studies. Br J Dermatol. 2014;170(3):548\u201356.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1962_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Thaci D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1962_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1962_CR38","doi-asserted-by":"publisher","first-page":"2665961","DOI":"10.1080\/09546634.2026.2665961","volume":"37","author":"EL Simpson","year":"2026","unstructured":"Simpson EL, Prajapati VH, Bunick CG, et al. Long-term benefits of upadacitinib for atopic dermatitis: deep responses in patient-reported outcomes over 140 weeks from the measure up 1 and measure up 2 clinical trials. J Dermatolog Treat. 2026;37(1):2665961.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1962_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","volume":"99","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Iizuka H, Nemoto O, Shimabe M, Furukawa Y, Kikuta N, et al. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci. 2020;99(2):82\u20139.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"1962_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/jdv.70165","volume":"40","author":"M Gooderham","year":"2026","unstructured":"Gooderham M, Ameen M, Hong HC-h, et al. Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2026;40(5):876\u201386.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1962_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1398-9995.2008.01683.x","volume":"63","author":"A Wollenberg","year":"2008","unstructured":"Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742\u201350.","journal-title":"Allergy"},{"issue":"6","key":"1962_CR42","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1365-2133.2008.08813.x","volume":"159","author":"D Tha\u00e7i","year":"2008","unstructured":"Tha\u00e7i D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0\u00b703% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348\u201356.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01962-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:21:20Z","timestamp":1792563680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01962-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":42,"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01962-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"5 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andreas Wollenberg has served as an adviser or paid speaker for or participated in clinical trials (with honorarium paid to the institution) sponsored by AbbVie; Aileens; Alentis; Almirall R&D, S.A.; Amgen; Beiersdorf; Bioderma; Bioproject; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Chugai; DKSH; Eli Lilly and Company; Galapagos; Galderma; Glenmark; GSK; Hans Karrer; Hexal; Janssen; Kyowa Kirin; LEO Pharma; L\u2019Or\u00e9al; Maruho; MedImmune; MSD; Mylan; Novartis; Pfizer; Pierre Fabre; Regeneron; Sandoz; Santen; Sanofi; and UCB. Peter Lio has received grants as an investigator, honoraria for lecturing, and\/or consulting fees from AbbVie, AOBiome, Arbonne, Burt\u2019s Bees, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Franklin Bioscience\/Altus Labs, Incyte, IntraDerm, Johnson & Johnson, Kiniksa, La\u00a0Roche-Posay\/L\u2019Or\u00e9al, LEO Pharma, Menlo Therapeutics, The National Eczema Association, Pfizer, Pierre Fabre, Realm Therapeutics, Sanofi, Theraplex, TopMD, UCB, Unilever, and Verrica Pharmaceuticals. Jose Manuel Carrascosa has served as an adviser and\/or paid speaker for and\/or participated in clinical trials sponsored by AbbVie; Almirall R&D, S.A.; Amgen; Boehringer Ingelheim; Galderma; Janssen-Cilag; LEO Pharma; Eli Lilly and Company; Novartis; Pfizer; Sanofi; Sandoz; and Bristol Myers Squibb. Jose Manuel Carrascosa is also an Editorial Board member of\n                      Dermatology and Therapy\n                      . Jose Manuel Carrascosa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions Linda Stein Gold has served as an investigator\/consultant and\/or speaker for Amgen, AbbVie, LEO Pharma, Arcutis, Incyte, Dermavant, Sanofi, Regeneron, Eli Lilly and Company, Bristol Myers Squibb, UCB, Janssen, Ortho Derm, and Galderma. James Del Rosso has received grants as an investigator, honoraria for lecturing, and\/or consulting fees from AbbVie, Amgen (Celgene), AOBiome, Aslan, Arbonne, Arcutis, Bausch Health (Ortho Derm), Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Ferndale, Galderma, Incyte, IntraDerm, Johnson & Johnson, La Roche-Posay\/L\u2019Or\u00e9al, LEO\u00a0Pharma, Menlo Therapeutics, Nektar, Pfizer, Pierre Fabre, Sanofi, Sun Pharma, Theraplex, UCB, Unilever, and Verrica Pharmaceuticals. Ken Igawa has received lecture fees from AbbVie GK, Eli Lilly Japan K.K., Maruho, Pfizer Japan Inc. and Sanofi K.K. H. Chih-ho Hong has been an investigator for and\/or a consultant for and\/or received honorarium from: Abbvie, Amgen, Arcutis, ASLAN pharmaceutics, Bausch Health, Biocon, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Inmagene, Iqvia, JAMP Pharma, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Organon, Oruka, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda, UCB. Leon Kircik has received grants and\/or honoraria from: Abbvie, Acambis, Amgen Inc. Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Assos Pharma, Astella Pharma US Inc., Asubio, Dermavant, Dermira, Dow Pharmaceutical Sciences Inc., Eli Lilly and Company, Ferndale Labroratories Inc., Galderma, Genentech Inc., GlaxoSmithKline PLC, Glenmark, Health Point LTD, Incyte, Innocutis, Innovail, Kyowakirin, LEO Pharma, L\u2019Oreal, Nano Bio, Novartis AG, Nucryst Pharmaceuticals Corp, Onset, OrthoDermatologics, OrthoNeutrogena, Promius, PediaPharma, PharmaDerm, Pfizer, PuraCap, Quinnova, Regeneron, Sanofi, SkinMedica Inc., Steifel Laboratories Inc., Sun Pharma, Taro, Triax, and Valean Pharmaceuticals Intl. Joseph Merola is a consultant and\/or investigator for AbbVie, Amgen, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Johnson & Johnson, Leo Pharma, Moonlake, Novartis, Pfizer, Sanofi, Regeneron, Sun Pharma, and UCB. Gaia Gallo, Yuxin Ding, and Chao Yang are employees and shareholders of Eli Lilly and Company. Eric Wolf was an employee and is a shareholder of Eli Lilly and Company, and is now an employee of Alumis Inc. Helena Agell is an employee of Almirall R&D, S.A. Christian Vestergaard has served as an adviser and\/or speaker and\/or has received fees or grant and\/or research support for and\/or has participated in clinical trials sponsored by AbbVie; Almirall R&D, S.A.; AstraZeneca; Eli Lilly and Company; Galderma; LEO Pharma; Novartis; OM Pharma; Pfizer; Pierre Fabre; and Sanofi.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All trials were approved by the applicable ethics review boards at each of the trial sites in North America, Europe, and the Asia\u2013Pacific region and were conducted in accordance with the ethical principles of the Declaration of Helsinki [\n                      \n                      ], Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Conference on Harmonization Guidelines for Good Clinical Practice. A full list of IRBs for each site is available in the Supplement to Silverberg et al. 2023 [\n                      \n                      ]. Informed consent was obtained from all patients before study procedures were initiated; for patients considered minors, written consent was obtained from the parent or legal guardian, as well as the assent of the minor.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}